Indication

KEVZARA® (sarilumab) is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).

In the management of Rheumatoid Arthritis…

Look deeper into value

Is your
Team
Missing
Something?

Look deeper into clinical value:
ILLUMINATING THE EVIDENCE

Targeted MOA that inhibits the effects
of chronically elevated IL-6

  • IL-6 is a pro-inflammatory cytokine produced by a variety of cell types, including local production by
    synovial and endothelial cells in joints affected by inflammatory processes such as RA1
  • KEVZARA, an IL-6Ri, specifically targets and binds with a high affinity to both soluble and membrane-
    bound IL-6 receptors,
    thereby inhibiting IL-6 signaling1,2

Observed Effects
of Sarilumab based on
PHARMACODYNAMIC studies1

  • The clinical significance of these findings is unknown.
  • *Following single-dose SC administration of sarilumab in patients with RA, absolute neutrophil
    counts decreased to the nadir between 3 and 4 days and thereafter recovered toward baseline.1

A ROBUST CLINICAL PROGRAM SPANNING MTX-IR
and TNF-IR POPULATIONS

Adult patients with moderately to severely active RA, diagnosed based on ACR criteria


MTX-IR and TNF-IR
PATIENT POPULATIONS

Two Pivotal, Randomized,
Double-Blind, Placebo-
controlled Studies

HEAD-TO-HEAD
SUPERIORITY STUDY AS A
MONOTHERAPY
VS ADALIMUMAB

Two Pivotal, Randomized,
Monotherapy Study
(not included in KEVZARA USPI)

Long-term SAFETY AND EFFICACY data

Open-label extension (OLE) study limitations and additional study context

  • These data are not included in the US Prescribing Information.
LONG-TERM SAFETY ANALYSIS

This was a comprehensive safety analysis from pooled studies of patients who received at least 1 dose of sarilumab in combination with DMARD(s) as of last data analysis on January 15, 2018.4

LONG-TERM EFFICACY ANALYSIS

Efficacy assessments in this analysis did not include all of the primary endpoints from the placebo-controlled period of the pivotal trials analyzed.

For analysis of no radiographic progression, linear extrapolation was used to impute missing data. Patients with missing data after the imputation were considered progressors.4

LOOK DEEPER INTO LONG-TERM SAFETY
AND EFFICACY DATA BY CONTACTING YOUR
SANOFI GENZYME ACCOUNT DIRECTOR

Given the limitations and context described above, caution should be used in interpreting these data. Look Deeper

Look deeper into economic value:
Exposing the bottom line

COMPETITIVELY PRICED amongst RA products

  • These products are not therapeutically equivalent and not interchangeable. This only reflects the acquisition price and not overall cost.
  • These products vary in their efficacy and safety, and they have different active ingredients. There are no data from clinical trials that
    provide differences in efficacy and safety and dosing as they relate to overall product costs. In addition, the quantities of a drug product
    a patient will require during treatment will vary.
  • Trademarks are the property of their respective owners.
  • *Annual WAC prices as of February 2021; subject to change.5

REDUCTIONS IN CRP LEVELS at Consistent q2W Dosing

  • The recommended dose of KEVZARA is 200 mg Q2W as an SC injection1
  • KEVZARA can be used with or without MTX or other conventional DMARD(s). Dosing of MTX and other conventional DMARDs may vary1
  • Reduce the dose to 150 mg Q2W for the management of neutropenia, thrombocytopenia, and elevated liver enzymes1
  • KEVZARA initiation is not recommended in patients with an ANC <2000 per mm3, platelet count <150,000 per mm3, or ALT or AST >1.5x ULN1

Predictable budget impact

IN A CLAIMS ANALYSIS OF PATIENTS PRESCRIBED SC ACTEMRA CONSISTING OF DATA
FROM TRUVEN MARKETSCAN AND OPTUM CLINFORMATICS DATABASES…6*

62%EITHER INITIATED
OR ESCALATED

TO THE HIGHER
WEEKLY DOSE

37%
ESCALATED
FROM Q2W
TO QW
DOSING

These dose
escalations can
almost double
projected
annual cost

KEVZARA is the only IL-6
inhibitor that does not
require dose escalation
1,7

  • These products are not therapeutically equivalent and not interchangeable. This only reflects the acquisition price and not overall cost.
  • These products vary in their efficacy and safety, and they have different active ingredients. There are no data from clinical trials that
    provide differences in efficacy and safety and dosing as they relate to overall product costs. In addition, the quantities of a drug product
    a patient will require during treatment will vary.
  • Trademarks are the property of their respective owners.
  • *Based on a retrospective cohort study from administrative medical and pharmacy claims data obtained from the Truven MarketScan database and the Optum Clinformatics database between October 1, 2012 and June 30, 2017.6

STUDIED IN COST-EFFECTIVENESS ANALYSIS VS MARKET LEADER

  • KEVZARA has been studied in a cost-effectiveness analysis as a monotherapy vs adalimumab monotherapy8*
  • KEVZARA as a monotherapy has been studied vs adalimumab monotherapy in an analysis of the incremental cost per effectively treated patient9†
LOOK DEEPER INTO COST-EFFECTIVENESS
DATA BY CONTACTING YOUR SANOFI
GENZYME ACCOUNT DIRECTOR
  • *Funding for this research was contributed to by the Institute for Clinical and Economic Review.8
  • Funding for this study was provided by Sanofi Genzyme and Regeneron Pharmaceuticals.9
  • Intended for use with payers, formulary committees, or other similar entities for purposes of population-based drug selection, coverage, and/or reimbursement decision-making, pursuant to FD&C Act Section 502(a).

Look deeper into practical value:
SURPASSING THE EXPECTED

Open distribution networks, button-free pen and prefilled syringe
with 14-day storage, and patient support programs1

Look deeper
into our in-network
specialty pharmacies*

Look deeper
into KEVZARA dosing
and administration

  • *Sanofi and Regeneron Pharmaceuticals, Inc. do not recommend any particular specialty pharmacy.
    However, health plans may recommend or mandate a particular pharmacy.
  • Coverage Support
  • Patient Access Support
  • Nurse Support
Look Deeper
into our
patient
support
programs

For more information, call KevzaraConnect at 1-844-KEVZARA (1-844-538-9272) Option 1,
Monday–Friday, 8 AM–9 PM Eastern time.

look deeper
into value

CLICK HERE TO CONTACT
YOUR SANOFI
GENZYME
ACCOUNT DIRECTOR
FOR MORE
INFORMATION.
YOU’LL BE GLAD YOU DID.

References:

  • KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc.
  • Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.
  • Burmester GR, et al. Ann Rheum Dis. 2017;76(5):840–847.
  • Data on file, Sanofi/Regeneron. EULAR poster SAT0172. June 2018.
  • Data on file. Analysource. Prices updated February 2021.
  • Punekar R, et al. AM Health Drug Benefits. 2019;12(8):400-409.
  • Actemra [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2019.
  • Whittington MD, et al. J Manag Care Spec Pharm. 2019;25(1):80-87.
  • Fournier M, et al. Clinicoecon Outcomes Res. 2019;11:117-128.